IRVINE, Calif., May 28, 2020 (Newswire.com) - betweenMD is very excited to announce our partnership with Oxitone, makers of the world's first FDA-cleared risk monitoring device.
Oxitone developed a wearable monitoring device, specifically designed and FDA-cleared for in-home use for patients with respiratory failure. This unique solution is for prolonged monitoring for those at risk for COVID-19, including those with other high-risk chronic conditions from the comfort of their home or in their workplace.
Oxitone's patented, trans-illumination optical technology provides REAL-TIME updates on all vital signs such as, but are not limited to, blood oxygen saturation, pulse rate, skin temperature, and pulse rate variability through our wearable medical-grade wrist-band.
“We are very excited about our partnership with betweenMD. Together we will be able to scale up our customer base across the US, develop advanced monitoring solutions and bring safety to patients and health professionals while dramatically reducing COVID-19 patients’ risk to miss lung failure event.” – Dr. Leon Eisen, Founder and CEO of Oxitone Medical.
Using betweenMD’s innovative health population management platform, Oxitone 1000M, the wearable wristband, can provide the critical and potentially life-saving data for those in our most at-risk population. Given the global nature of this pandemic and the demand, betweenMD and Oxitone will be partnering for a limited number of institutions to accelerate the deployment of this solution in the United States.
betweenMD is the authorized reseller for Oxitone 1000M in the U.S. With over 20 years of global healthcare experience, betweenMD is perfectly positioned to offer this state-of-the-art and HIPAA compliant health-monitoring platform to better lives and better society at large by monitoring potentially serious symptoms of COVID-19 or other chronic diseases. Through betweenMD, families can unlock this data to keep even a closer eye on their loved ones.
“Having met Leon Eisner, Ph.D. through Start-Up Health over seven years ago, we are thrilled to bring this solution to the United States at such a critical time when home-based monitoring is becoming a new normal. Given the nature of both the current pandemic and the rates of chronic disease in the U.S., it is our objective to deliver Oxitone solutions to multiple institutions. With initial deployments of 10 units, base packages of 50 units and large scale deployments of 1,000 units, we expect to have at least 10,000 units deployed in the US in the next year.” – Andy Quinn, CEO of betweenMD.